Teva Announces Submission of Biologics License Application for Fremanezumab to the U.S. FDA

JERUSALEM--(BUSINESS WIRE)--Oct. 17, 2017-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for fremanezumab, an...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news